Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020. This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA. This is in no way a thorou...

Today, we will be studying why Dicerna Pharmaceuticals ( DRNA ) is an attractive investment for 2020. Company overview Dicerna Pharmaceuticals is a small-cap biopharmaceutical company focused on developing innovative RNAi (RNA interference) therapies. The company is predominantly targeti...

In a statement , Alexion Pharmaceuticals (NASDAQ: ALXN ) says it has established a "strong foundation" to drive growth and boost shareholder value and does not plan to pursue an outright sale as proposed by shareholder Elliott Advisors. More news on: Alexion Pharmaceuticals, Inc., Healthc...